NuCana (NASDAQ:NCNA) Stock Price Down 6.4% – Should You Sell?

NuCana plc (NASDAQ:NCNA) was down 6.4% on Monday . The stock traded as low as $1.00 and last traded at $1.02. Approximately 54,601 shares traded hands during mid-day trading, a decline of 31% from the average daily volume of 79,077 shares. The stock had previously closed at $1.09.

NuCana Price Performance

The stock has a market capitalization of $2.70 million, a price-to-earnings ratio of -0.10 and a beta of 0.96. The stock has a 50 day moving average price of $1.11 and a 200-day moving average price of $2.15.

NuCana (NASDAQ:NCNA) last announced its earnings results on Monday, November 25th. The company reported ($2.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($3.49) by $1.21. As a group, research analysts forecast that NuCana plc will post -13.42 earnings per share for the current year.

Hedge Funds Weigh In On NuCana

Institutional investors and hedge funds have recently bought and sold shares of the business. Virtu Financial LLC purchased a new position in NuCana in the 4th quarter worth approximately $48,000. Two Sigma Securities LLC purchased a new stake in shares of NuCana in the fourth quarter valued at approximately $25,000. Schonfeld Strategic Advisors LLC acquired a new stake in shares of NuCana in the fourth quarter valued at approximately $54,000. Finally, Citadel Advisors LLC purchased a new position in NuCana during the fourth quarter worth approximately $30,000. 44.00% of the stock is currently owned by institutional investors and hedge funds.

NuCana Company Profile

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing ProTides medicines to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells.